Abstract
Although the role of the renin-angiotensin system in the pathogenesis of hypertension remains a subject of active investigation and debate, there is increasing recognition that pharmacological inhibition of the system can be a potent mechanism by which blood pressure can be lowered. Bühler and coworkers,1 in examining the renin-lowering effect of β-adrenergic blockade in patients with essential and malignant hypertension, found that propranolol in low to moderate doses lowers blood pressure in high an normal renin forms of hypertension but does not significantly lower blood pressure in low renin hypertensive pateints. These findings have been confirmed by many investigators using propranolol and a variety of other β-blocking agents.2–4 It is also now apparent that propranolol can actually raise blood pressure in some patients with low levels of renin activity.5
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bühler FR, Laragh JH, Baer L, et al: Propranolol inhibition of renin secretion: A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 287:1209–1214, 1972.
Hollifield JW, Sherman K, Vander Zwag R, et al: Proposed mechanism of propranolol’s antihypertensive effect in essential hypertension. N EnglJ Med 295:68–73, 1976.
Menard J, Bertagna X, N’Guyen PT, et al: Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker). Am J Med 60:886–890, 1976.
MacGregor GA, Dawes P: Antihypertensive effect of propranolol and spironolactone in relation to plasma angiotensin II. Clin Sci Mol Med 50:18p, 1976.
Drayer JIM, Keim HY, Weber MA, et al: Unexpected pressor responses to propranolol in essential hypertension. Am J Med 60:897–903, 1976.
Streeten DHP, Anderson GH, Freiberg JM, et al: Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension. N Engl J Med 292:657–662, 1975.
Brunner HR, Gavras H, Laragh JH, et al: Hypertension in man: Exposure of the renin and sodium components using angiotensin II blockade. Circ Res 34(suppl l):35–43, 1974.
Case DB, Wallace JM, Keim HJ, et al: Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med 60:825–836, 1976.
Hollenberg NK, Williams GH, Burger B, et al: Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with l-sar-8-ala-angiotensin II in normal man. J Clin Invest 57:39–46, 1976.
Case DB, Wallace JM, Keim HJ, et al: Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 296:641–646, 1977.
Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 196:441–444, 1977.
Ferguson RK, Turini GA, Brunner HR, et al: A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 1:775–778, 1977.
Murthy VS, Waldron TL, Goldberg ME, et al: Inhibition of angiotensin converting enzyme by SQ 14225 in conscious rabbits. Eur J Pharmacol 46:201–212, 1977.
Colman RW, Girey GJD, Zacest R, et al: The human plasma kallikrein-kinin system. Prog Hematol 7:255–298, 1971.
Gavras H, Brunner HR, Turini G A, et al: Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N EnglJ Med 298:991–995, 1978.
Laragh JH, Baer L, Brunner HR, et al: Renin, angiotensin, aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 52:633, 1972.
Sealey JE, Laragh JH: How to do a plasma renin assay. Cardiovasc Med 2:1079–1092, 1977.
Bühler FR, Sealey JE, Laragh JH: Radioimmunoassay of plasma aldosterone, in Laragh JH (ed): Hypertension Manual. New York, Dun-Donnelley, 1974, pp 655–669.
MacKenzie JK, Clements JA: Simplified radioimmunoassay of serum aldosterone utilizing increased antibody specificity. J Clin Endocrinol Metab 38:622–627, 1974.
Sealey JE, Bühler FR, Laragh JH, et al: Aldosterone excretion: Physiologic variations in man measured by radioimmunoassay or double isotope dilution. Circ Res 31:367–378, 1972.
Tarazi RC, Dustan HP: Beta-adrenergic blockade in hypertension: Practical and theoretic implications of long term hemodynamic variations. Am J Cardiol 29:633–640, 1972.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Plenum Publishing Corporation
About this chapter
Cite this chapter
Case, D.B., Atlas, S.A., Laragh, J.H., Sealey, J.E., Sullivan, P.A., McKinstry, D.N. (1980). Clinical Experience with Blockade of the Renin-Angiotensin-Aldosterone System by an Oral Converting Enzyme Inhibitor (SQ 14,225, Captopril) in Hypertensive Patients. In: Case, D.B., Sonnenblick, E.H., Laragh, J.H. (eds) Captopril and Hypertension. Topics in Cardiovascular Disease. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9179-5_15
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9179-5_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-9181-8
Online ISBN: 978-1-4615-9179-5
eBook Packages: Springer Book Archive